Literature DB >> 25282472

Intraductal neoplasms of the pancreas.

Günter Klöppel1, Olca Basturk2, Anna Melissa Schlitter3, Björn Konukiewitz3, Irene Esposito3.   

Abstract

There are three types of pancreatic neoplasms that predominantly have an intraductal growth pattern: the common, usually cystic, intraductal papillary mucinous neoplasms (IPMNs); the rare, usually solid intraductal tubulopapillary neoplasms (ITPNs); and the rare intraductal tubular pyloric gland-type adenoma. In addition to these three tumor types, pancreatic neoplasms with a usually solid growth pattern such as acinar cell carcinomas, neuroendocrine tumors, and undifferentiated carcinomas may present, though very rarely, as predominantly intraductally growing neoplasms. IPMNs can be subclassified into main duct and branch duct tumors; into low- and high-grade dysplasia groups; and into tumors with intestinal, pancreatobiliary, oncocytic, or gastric cellular differentiation. The intestinal-, pancreatobiliary-, and oncocytic-type IPMNs occur predominantly in the main duct of the head of the pancreas and more commonly progress to invasive adenocarcinomas. The gastric-type IPMNs are frequently multifocal, occur predominantly in the branch ducts of the uncinate process, and have a low risk of progressing to invasive carcinoma. The prognosis for patients with an IPMN depends largely on the subtype and the presence and the stage of an invasive carcinoma. ITPNs are nodular tumors, often in the pancreatic head, and composed of densely packed tubular glands. Molecular genetics reveal KRAS, GNAS, and RNF43 as the most frequently mutated genes in IPMNs, while ITPNs show wild-type KRAS. Recent progress in genetic sequencing of pancreatic neoplasms and the identification of specific genetic mutations also holds promise for the future development of novel gene-based diagnostic tests in intraductal neoplasms of the pancreas that might even be used in preoperative conditions.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genetics; Intraductal papillary mucinous neoplasm; Intraductal tubulopapillary neoplasm; Pancreatic intraductal tumor; Prognosis

Mesh:

Year:  2014        PMID: 25282472     DOI: 10.1053/j.semdp.2014.08.005

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN: 0740-2570            Impact factor:   3.464


  25 in total

1.  Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.

Authors:  Olca Basturk; Michael F Berger; Hiroshi Yamaguchi; Volkan Adsay; Gokce Askan; Umesh K Bhanot; Ahmet Zehir; Fatima Carneiro; Seung-Mo Hong; Giuseppe Zamboni; Esra Dikoglu; Vaidehi Jobanputra; Kazimierz O Wrzeszczynski; Serdar Balci; Peter Allen; Naoki Ikari; Shoko Takeuchi; Hiroyuki Akagawa; Atsushi Kanno; Tooru Shimosegawa; Takanori Morikawa; Fuyuhiko Motoi; Michiaki Unno; Ryota Higuchi; Masakazu Yamamoto; Kyoko Shimizu; Toru Furukawa; David S Klimstra
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 2.  Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have.

Authors:  Marta Herreros-Villanueva; Luis Bujanda
Journal:  Ann Transl Med       Date:  2016-04

3.  Intraductal Tubulopapillary Neoplasm of the Pancreas: A Clinicopathologic and Immunohistochemical Analysis of 33 Cases.

Authors:  Olca Basturk; Volkan Adsay; Gokce Askan; Deepti Dhall; Giuseppe Zamboni; Michio Shimizu; Karina Cymes; Fatima Carneiro; Serdar Balci; Carlie Sigel; Michelle D Reid; Irene Esposito; Helena Baldaia; Peter Allen; Günter Klöppel; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2017-03       Impact factor: 6.394

4.  The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.

Authors:  I M Modlin; M Kidd; L Bodei; I Drozdov; H Aslanian
Journal:  Am J Gastroenterol       Date:  2015-06-02       Impact factor: 10.864

5.  Intraductal tubulopapillary neoplasms of the bile ducts: clinicopathologic, immunohistochemical, and molecular analysis of 20 cases.

Authors:  Anna Melissa Schlitter; Kee-Taek Jang; Günter Klöppel; Burcu Saka; Seung-Mo Hong; Hyejeong Choi; George Johan Offerhaus; Ralph H Hruban; Yoh Zen; Björn Konukiewitz; Ivonne Regel; Michael Allgäuer; Serdar Balci; Olca Basturk; Michelle D Reid; Irene Esposito; Volkan Adsay
Journal:  Mod Pathol       Date:  2015-06-26       Impact factor: 7.842

6.  Clinicopathological Features of Intraductal Papillary Mucinous Neoplasms of Pancreas in a Tertiary Care Center: A 14 Year Retrospective Study.

Authors:  Thomas Alex Kodiatte; Deepak Burad; Manbha L Rymbai
Journal:  J Clin Diagn Res       Date:  2016-08-01

Review 7.  MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions.

Authors:  Yasmin G Hernandez; Aimee L Lucas
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

8.  Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis.

Authors:  Michelle D Reid; Christina R Stallworth; Melinda M Lewis; Gizem Akkas; Bahar Memis; Olca Basturk; Volkan Adsay
Journal:  Cancer Cytopathol       Date:  2015-09-28       Impact factor: 5.284

9.  The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes.

Authors:  Olca Basturk; Marcus Tan; Umesh Bhanot; Peter Allen; Volkan Adsay; Sasinya N Scott; Ronak Shah; Michael F Berger; Gokce Askan; Esra Dikoglu; Vaidehi Jobanputra; Kazimierz O Wrzeszczynski; Carlie Sigel; Christine Iacobuzio-Donahue; David S Klimstra
Journal:  Mod Pathol       Date:  2016-06-10       Impact factor: 7.842

Review 10.  Clinicopathological features and surgical outcomes of intraductal tubulopapillary neoplasm of the pancreas: a systematic review.

Authors:  Keiichi Date; Takehiro Okabayashi; Yasuo Shima; Jun Iwata; Tatsuaki Sumiyoshi; Akihito Kozuki; Sojiro Morita; Yasuhiro Hata; Yoshihiro Noda; Akihito Nishioka; Manabu Matsumoto
Journal:  Langenbecks Arch Surg       Date:  2016-03-21       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.